Bicycle Therapeutics plc (BCYC)

GB — Healthcare Sector
Peers: IDYA  ANAB  MGTX  KROS  FIXX  TNYA  IGMS  GLUE  STOK  MRUS  INBX  IMTXW  SEER  ORIC  ANEB  CGEM  CCCC  ADAG  ACRV  MLYS 

Automate Your Wheel Strategy on BCYC

With Tiblio's Option Bot, you can configure your own wheel strategy including BCYC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol BCYC
  • Rev/Share 0.3719
  • Book/Share 10.6989
  • PB 0.6636
  • Debt/Equity 0.0112
  • CurrentRatio 14.8567
  • ROIC -0.2913

 

  • MktCap 491336721.0
  • FreeCF/Share -2.632
  • PFCF -2.6977
  • PE -2.417
  • Debt/Assets 0.0094
  • DivYield 0
  • ROE -0.2511

 

  • Rating C+
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 1
  • P/B Score 4
  • D/E Score 4

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation BCYC RBC Capital Mkts -- Outperform -- $35 Sept. 6, 2024

News

Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
BCYC
Published: May 22, 2025 by: Business Wire
Sentiment: Neutral

CAMBRIDGE, England, & BOSTON--(BUSINESS WIRE)--Bicycle Therapeutics plc (NASDAQ: BCYC), a pharmaceutical company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced the poster presentation of two abstracts at the 2025 American Society for Clinical Oncology (ASCO) Annual Meeting, taking place May 30-June 3 in Chicago. Poster Presentation Details: Title: Phase 1/2 Duravelo-1 study: Preliminary results of Nectin.

Read More
image for news Bicycle Therapeutics Announces Poster Presentations at the 2025 ASCO Annual Meeting
Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted
BCYC
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Neutral

Bicycle Therapeutics focuses on novel conjugated targeted therapies for cancer, with promising early results but no clear evidence of superior efficacy yet. Their lead compound, zelenectide pevedotin, shows potential in urothelial carcinoma with a 45% response rate, but more robust studies are needed. Financially, BCYC is well-capitalized with $879.5 million in cash, providing a runway into 2027 despite high operating expenses.

Read More
image for news Bicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This Discounted

About Bicycle Therapeutics plc (BCYC)

  • IPO Date 2019-05-23
  • Website https://www.bicycletherapeutics.com
  • Industry Biotechnology
  • CEO Kevin Lee
  • Employees 305
Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics. Its lead product candidate is BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease. The company's oncology product candidates also comprise BT5528, a BTC that is in a Phase I/II clinical trial targeting EphA2; and BT8009, which is in Phase I/II clinical trial targeting Nectin-4. In addition, it is developing THR-149, a plasma kallikrein inhibitor that completed Phase II clinical trials for the treatment of diabetic macular edema; BT7480, a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455, an EphA2/CD137 Bicycle TICA, which is in preclinical studies; and BT1718, a BTC that target tumors, that is in Phase I/IIa clinical trial that express Membrane Type 1 matrix metalloproteinase. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas, such as anti-infective, cardiovascular, ophthalmology, and respiratory indications. It has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca, Sanofi, Oxurion, and the Dementia Discovery Fund; and discovery collaboration and license agreement with Genentech for the discovery and development of Bicycle peptides for multiple immuno-oncology targets. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.